Q1 2026 Corcept Therapeutics Inc Earnings Call Transcript
Key Points
- Corcept Therapeutics Inc (CORT) reported a revenue increase to $164.9 million in Q1 2026, up from $157.2 million in the same period last year.
- The company has raised its 2026 revenue guidance to a range of $950 million to $1.05 billion.
- The FDA approved LIFYORLI for the treatment of platinum-resistant ovarian cancer, three-and-a-half months ahead of its PDUFA date.
- The CATALYST and MOMENTUM trials have shown promising results, indicating that hypercortisolism is a significant factor in resistant diabetes and hypertension.
- Corcept Therapeutics Inc (CORT) expects its Cushing's syndrome business to grow to at least $2 billion in annual revenue by the end of the decade.
- Corcept Therapeutics Inc (CORT) reported a net loss of $31.8 million in Q1 2026, compared to a net income of $20.5 million in the same period last year.
- Revenue was impacted by insurance reauthorization procedures that interrupted patient coverage, leading to a temporary dip.
- The transition to a new specialty pharmacy vendor caused a backlog in insurance prior-authorization, affecting revenue.
- The company faces challenges in scaling its pharmacy network to handle increasing prescription volumes.
- There are ongoing uncertainties and risks associated with forward-looking statements, as highlighted in their financial reports.
Thank you for standing by. Welcome to Corcept Therapeutics' first-quarter 2026 earnings conference call.
(Operator Instructions)
I would now like to hand the call over to Atabak Mokari, CFO. Please go ahead.
Hello, everyone. Good afternoon and thank you for joining us.
Today, we issued a press release announcing our financial results for the first quarter and providing a corporate update. A copy is available at corcept.com. Our complete financial results will be available when we file our Form 10-Q with the SEC.
Today's call is being recorded. A replay will be available at the Investors' Past Events tab of our website.
Statements during this call, other than statements of historical fact, are forward-looking statements, based on our plans and expectations, that are subject to risks and uncertainties, which might cause actual results to be materially different from those such statements expressed or implied.
The risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
